Abstract: Electrostatic chuck (ESC) apparatuses and systems are provided. An ESC may have one or more chucking electrodes and a blocking electrode that surrounds the chucking electrodes. The blocking electrode may reduce non-uniformities in semiconductor processing operations performed with the ESC. In some implementations, the blocking electrode is positioned beneath the chucking electrodes.

Abstract: An apparatus for massage of a user in a reclined position, having a housing structure having a base portion with a user support surface for supporting the user in a reclined position, and a massage assembly disposed adjacent the user support surface, the massage assembly including at least one fluid storage reservoir, at least one fluid bag disposed within the user support surface, and at least one fluid pump in fluid communication with both the at least one fluid storage reservoir and the at least one fluid bag, wherein the at least one fluid pump is configured to circulate fluid from the at least one fluid storage reservoir to the at least one fluid bag.

Abstract: A decorative assembly having a finial element and a fastening element configured to couple with the finial element, where the fastening element may be mounted to a surface such as a wall. The finial element may come in various shapes and sizes, including without limitation ball shape, end cap, cut acrylic, tiered glass, to name a few. The decorative assembly may be utilized for decorative purposes accenting the end of objects such as drapery or curtain rods.

Abstract: An apparatus for cryotherapy treatment of a user in a reclined position, including a housing structure having a base portion with a user support surface for supporting the user in a reclined position, and a first fluid storage reservoir, a first fluid bag disposed within the user support surface, and a first fluid pump in fluid communication with both the first fluid storage reservoir and the first fluid bag, wherein the first pump is configured to circulate fluid from the first fluid storage reservoir to the first fluid bag.

Abstract: An apparatus for massage of a user in a reclined position, including a housing structure having a base portion with a user support surface for supporting the user in a reclined position, and a top cover portion that extends the full length of the base portion so that the user being disposed or the user support surface is disposed between the base portion and the top cover portion, a massage assembly disposed adjacent the user support surface, and a video display disposed on an inner surface of the top cover portion so that the video display is visible to the user disposed on the user support surface.

Abstract: A pole caddy comprises a pole, one or more collars to each of which is removably attached a cantilevered shelf preferably made of metal wire. Each collar, preferably made of structural plastic, has a downwardly extending tab that runs along the pole. The tab has a contact portion, preferably an elastomer pad, in contact with the exterior of the pole. The weight of the shelf and any articles on the shelf applies force through a brace part of the shelf, to cause the tab to frictionally engage the pole and thus hold the shelf at a desired elevation.

Abstract: A lockable mounting system comprising a cylindrical mount having a pair of radially extending flanges and a tubular collar with a cooperatively shaped recess located on an inner surface to engage with the flanges of the mount. In use, the collar is inserted over the mount such that that the recess is able to pass over the flanges when they are rotationally aligned. The collar is prevented from becoming detached from the mount when the recess and flanges are rotationally misaligned.

Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance sterin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.

Abstract: A pharmaceutical and/or veterinary formulation comprising about 2-30% (w/w) (on an active basis) of at least one active agent, about 0.5-20.0% (w/w) of a pore-foaming agent and the balance stearin. Such formulations provided release of the at least one active agent in humans and other animals for periods of 7 days up to about 2 years.

Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance sterin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.

Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance stearin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.

Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15 % (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5 % (w/w) lecithin and the balance sterin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.

Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance stearin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.

Abstract: The present invention provides a method for the treatment or prevention of eczema/dermatitis. This method involves the administration of Peptide T or its derivatives or analogues. Preferred compounds used in the method include: 1) D-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr-NH.sub.2 ; 2) Ala-Ser-thr-thr-Thr-Asn-Tyr-Thr, 3) D-Ala-Ser-Thr-Thr-Thr-Asn-Tyr-Thr, 4) D-Ala-Ala-Ser-Ser-Asn-Tyr-Met; 5) Thr-Asp-Asn-Tyr-Thr, 6) Thr-Thr-Ser-Tyr-Thr, 7) Thr-Thr-Asn-Tyr-Thr, 8) D-Thr-Thr-Tyr-D-Thr, 9) D-Ala-Ser-D-Thr-Thr-D-Thr-Asn-Tyr-D-Thr-NH.sub.2 ; 10) D-Ser-Ser-D-Thr-Thr-D-Thr-Thr-Tyr-D-Thr-NH.sub.2.